Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India

H. K. Chopra; G. S. Wander; Tiny Nair; C. K. Ponde; Navin C. Nanda; Jagat Narula; Saumitra Ray; K. Venugopal; S. S. Iyengar; R. R. Kasliwal; Praveen Chandra; Sunil Prakash; Sandeep Bansal; D. S. Rana; Prafulla Kerkar; Arup Dasbiswas; J. P.S. Sawhney; S. Shanmungasundram; Viveka Kumar; I. B. Vijayalakshmi; A. K. Pancholia; Vinod Sharma; Aditya Kapoor; Onkar C. Swami; H. S. Isser; Vishal Rastogi; Y. K. Arora; Ashok K. Omar; Sunil Sathe; Rajeeve Rajput; D. Prabhakar; G. Justin Paul; Priya Jagia; Poonam Malhotra; G. Suryaprakash; Vinod Mittal; Manish Jagia; A. Jabir; S. S. Mishra; S. N. Routray; Ajay Kumar Sinha; Mohan Bhargava; Kiran Mahmood; Shreya Lal; Dhammdeep Dabhade; Mona Bhatia; Pramila Kalra; V. K. Katyal; Rohit Tandon; Rahul Grover; Abhinav Chhabra; N. R. Shastry

doi:10.5005/japi-11001-0230

Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India

H. K. Chopra, G. S. Wander, Tiny Nair, C. K. Ponde, Navin C. Nanda, Jagat Narula, Saumitra Ray, K. Venugopal, S. S. Iyengar, R. R. Kasliwal, Praveen Chandra, Sunil Prakash, Sandeep Bansal, D. S. Rana, Prafulla Kerkar, Arup Dasbiswas, J. P.S. Sawhney, S. Shanmungasundram, Viveka Kumar, I. B. VijayalakshmiA. K. Pancholia, Vinod Sharma, Aditya Kapoor, Onkar C. Swami, H. S. Isser, Vishal Rastogi, Y. K. Arora, Ashok K. Omar, Sunil Sathe, Rajeeve Rajput, D. Prabhakar, G. Justin Paul, Priya Jagia, Poonam Malhotra, G. Suryaprakash, Vinod Mittal, Manish Jagia, A. Jabir, S. S. Mishra, S. N. Routray, Ajay Kumar Sinha, Mohan Bhargava, Kiran Mahmood, Shreya Lal, Dhammdeep Dabhade, Mona Bhatia, Pramila Kalra, V. K. Katyal, Rohit Tandon, Rahul Grover, Abhinav Chhabra, N. R. Shastry

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-Transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).

Original language	English
Pages (from-to)	73-82
Number of pages	10
Journal	Journal of the Association of Physicians of India
Volume	71
Issue number	4
DOIs	https://doi.org/10.5005/japi-11001-0230
State	Published - Apr 2023

Access to Document

10.5005/japi-11001-0230

Cite this

Chopra, H. K., Wander, G. S., Nair, T., Ponde, C. K., Nanda, N. C., Narula, J., Ray, S., Venugopal, K., Iyengar, S. S., Kasliwal, R. R., Chandra, P., Prakash, S., Bansal, S., Rana, D. S., Kerkar, P., Dasbiswas, A., Sawhney, J. P. S., Shanmungasundram, S., Kumar, V., ... Shastry, N. R. (2023). Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India. Journal of the Association of Physicians of India, 71(4), 73-82. https://doi.org/10.5005/japi-11001-0230

@article{eff66ce9ab084ac69ae049102f4ec926,

title = "Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India",

abstract = "Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-Transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).",

author = "Chopra, {H. K.} and Wander, {G. S.} and Tiny Nair and Ponde, {C. K.} and Nanda, {Navin C.} and Jagat Narula and Saumitra Ray and K. Venugopal and Iyengar, {S. S.} and Kasliwal, {R. R.} and Praveen Chandra and Sunil Prakash and Sandeep Bansal and Rana, {D. S.} and Prafulla Kerkar and Arup Dasbiswas and Sawhney, {J. P.S.} and S. Shanmungasundram and Viveka Kumar and Vijayalakshmi, {I. B.} and Pancholia, {A. K.} and Vinod Sharma and Aditya Kapoor and Swami, {Onkar C.} and Isser, {H. S.} and Vishal Rastogi and Arora, {Y. K.} and Omar, {Ashok K.} and Sunil Sathe and Rajeeve Rajput and D. Prabhakar and {Justin Paul}, G. and Priya Jagia and Poonam Malhotra and G. Suryaprakash and Vinod Mittal and Manish Jagia and A. Jabir and Mishra, {S. S.} and Routray, {S. N.} and Sinha, {Ajay Kumar} and Mohan Bhargava and Kiran Mahmood and Shreya Lal and Dhammdeep Dabhade and Mona Bhatia and Pramila Kalra and Katyal, {V. K.} and Rohit Tandon and Rahul Grover and Abhinav Chhabra and Shastry, {N. R.}",

year = "2023",

month = apr,

doi = "10.5005/japi-11001-0230",

language = "English",

volume = "71",

pages = "73--82",

journal = "Journal of the Association of Physicians of India",

issn = "0004-5772",

publisher = "Journal of Association of Physicians of India",

number = "4",

}

Chopra, HK, Wander, GS, Nair, T, Ponde, CK, Nanda, NC, Narula, J, Ray, S, Venugopal, K, Iyengar, SS, Kasliwal, RR, Chandra, P, Prakash, S, Bansal, S, Rana, DS, Kerkar, P, Dasbiswas, A, Sawhney, JPS, Shanmungasundram, S, Kumar, V, Vijayalakshmi, IB, Pancholia, AK, Sharma, V, Kapoor, A, Swami, OC, Isser, HS, Rastogi, V, Arora, YK, Omar, AK, Sathe, S, Rajput, R, Prabhakar, D, Justin Paul, G, Jagia, P, Malhotra, P, Suryaprakash, G, Mittal, V, Jagia, M, Jabir, A, Mishra, SS, Routray, SN, Sinha, AK, Bhargava, M, Mahmood, K, Lal, S, Dabhade, D, Bhatia, M, Kalra, P, Katyal, VK, Tandon, R, Grover, R, Chhabra, A & Shastry, NR 2023, 'Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India', Journal of the Association of Physicians of India, vol. 71, no. 4, pp. 73-82. https://doi.org/10.5005/japi-11001-0230

TY - JOUR

T1 - Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure

T2 - consensus statement from India

AU - Chopra, H. K.

AU - Wander, G. S.

AU - Nair, Tiny

AU - Ponde, C. K.

AU - Nanda, Navin C.

AU - Narula, Jagat

AU - Ray, Saumitra

AU - Venugopal, K.

AU - Iyengar, S. S.

AU - Kasliwal, R. R.

AU - Chandra, Praveen

AU - Prakash, Sunil

AU - Bansal, Sandeep

AU - Rana, D. S.

AU - Kerkar, Prafulla

AU - Dasbiswas, Arup

AU - Sawhney, J. P.S.

AU - Shanmungasundram, S.

AU - Kumar, Viveka

AU - Vijayalakshmi, I. B.

AU - Pancholia, A. K.

AU - Sharma, Vinod

AU - Kapoor, Aditya

AU - Swami, Onkar C.

AU - Isser, H. S.

AU - Rastogi, Vishal

AU - Arora, Y. K.

AU - Omar, Ashok K.

AU - Sathe, Sunil

AU - Rajput, Rajeeve

AU - Prabhakar, D.

AU - Justin Paul, G.

AU - Jagia, Priya

AU - Malhotra, Poonam

AU - Suryaprakash, G.

AU - Mittal, Vinod

AU - Jagia, Manish

AU - Jabir, A.

AU - Mishra, S. S.

AU - Routray, S. N.

AU - Sinha, Ajay Kumar

AU - Bhargava, Mohan

AU - Mahmood, Kiran

AU - Lal, Shreya

AU - Dabhade, Dhammdeep

AU - Bhatia, Mona

AU - Kalra, Pramila

AU - Katyal, V. K.

AU - Tandon, Rohit

AU - Grover, Rahul

AU - Chhabra, Abhinav

AU - Shastry, N. R.

PY - 2023/4

Y1 - 2023/4

N2 - Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-Transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).

AB - Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-Transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).

UR - http://www.scopus.com/inward/record.url?scp=85164561955&partnerID=8YFLogxK

U2 - 10.5005/japi-11001-0230

DO - 10.5005/japi-11001-0230

M3 - Review article

AN - SCOPUS:85164561955

SN - 0004-5772

VL - 71

SP - 73

EP - 82

JO - Journal of the Association of Physicians of India

JF - Journal of the Association of Physicians of India

IS - 4

ER -

Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India

Abstract

Access to Document

Fingerprint

Cite this